Home>Publications>Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Abstract not available at this time.
RTI Health Solutions®
The power of knowledge. The value of understanding.
Steeped in a tradition of rigor and process, we maintain a legacy of setting the scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value and potential of your products. Learn more.